ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

Related Keywords

France ,Karine Lignel ,Philippe Genne ,Laure Lamm Coutard ,Maria Osipova ,Fabrice Viviani ,Oncodesign Servicesfeb ,Catherine Genne ,Kamel Besseghir ,Jan Hoflack ,Contract Research Organization ,Distribution To Oncodesign Services ,Services Oncodesign ,Drug Discovery Services ,Oncodesign Services ,Oncodesign Group ,Founder Of Oncodesign Services ,From Oncodesign Servicesfeb ,Elyan Partners ,Control Block ,Oncodesign Precision Medicine ,Drug Discovery ,Precision Medicine ,Discovery Services ,Maxence De Vienne ,Chief Executive ,Deputy Managing ,Supervisory Board ,Vincent Man ,Inflammation ,Medicine ,Ncology ,Reclinical ,Research ,